论文部分内容阅读
Organometallic drugs have often occupied a difficult niche in terms of therapeutic value.Bioactive metal containing compounds can demonstrate high efficacy but can also suffer from a low bioavailability.Predominantly this is as a result of poor solubility under physiological conditions which means that it is difficult to reach beneficial drug concentrations in-vivo without the dose becoming toxic and many potential antibacterial and anticancer drugs have been abandoned due to related insurmountable formulation issues.